Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Genetically Engineered Cells (CART123) in Combination with Ruxolitinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Trial Status: closed to accrual

This phase I trial tests the safety, side effects, and best dose of ruxolitinib followed by CART123 cells for treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Chimeric antigen receptor (CAR) T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein, such as CD123, on the patient’s tumor cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Ruxolitinib is a type of drug called a JAK inhibitor, and it works by targeting and blocking JAK proteins. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking these proteins, ruxolitinib may slow JAK signaling and help the body make the right amount of blood cells. Giving CART123 cells in combination with ruxolitinib may be safe, tolerable, and/or effective in treating patients with relapsed or refractory AML.